Tempest Therapeutics, Inc. (TPST) Stock Price & Analysis
Tempest Therapeutics, Inc. (TPST) rose 0.00% to USD 1.27 as of June 10, 2026 at 04:40 UTC, according to Nexqual real-time market data.
TPST last closed at USD 1.27; the session ranged USD 1.24–1.29 on volume of 70,152 shares. Market capitalization is $18.80M, with a 52-week range of USD 1.23–12.23 (NCM). Source: Nexqual, June 10, 2026 at 04:40 UTC.
Key Statistics (as of June 10, 2026 at 04:40 UTC)
| Price | USD 1.27 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 1.27 |
| Open | USD 1.24 |
| Day Range | USD 1.24 – 1.29 |
| 52-Week Range | USD 1.23 – 12.23 |
| Volume | 70,152 shares |
| Market Cap | $18.80M |
| Exchange | NCM |
Technical Analysis (TPST)
Nexqual's technical model rates TPST "SELL" based on 1 bullish and 5 bearish signals across 123 daily candles, as of June 10, 2026 at 04:40 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 31.13 (neutral) |
| vs SMA50 | Below (USD 1.78) |
| MACD | -0.17 (negative) |
Analyst Ratings (TPST)
Wall Street analysts rate TPST "None" based on 1 analysts, with a mean price target of USD 11 (range USD 11–11), per Nexqual as of June 10, 2026 at 04:40 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 1 |
| Mean Target | USD 11 |
| High Target | USD 11 |
| Low Target | USD 11 |
| Buy / Hold / Sell | 1 / 0 / 0 |
Earnings (TPST)
| Next Earnings Date | 2026-08-11 |
|---|---|
| EPS Estimate | USD -0.3 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.5 vs est -0.28 ▼ miss |
| 2025-12-31 | USD -0.62 vs est -0.62 ▲ beat |
| 2025-09-30 | USD -0.79 vs est -3.27 ▲ beat |
| 2025-06-30 | USD -2.07 vs est -3.23 ▲ beat |
Source: Nexqual, June 10, 2026 at 04:40 UTC.
Financials & Fundamentals (TPST)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -203.63% |
| Debt / Equity | 122.09 |
| Current Ratio | 2.5 |
| Total Cash | $7.71M |
| Total Debt | $8.14M |
| Free Cash Flow | $-17.59M |
Source: Nexqual, June 10, 2026 at 04:40 UTC.
Financial Health Score (TPST)
Nexqual rates Tempest Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 04:40 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $8M cash vs $8M debt |
| Cash Flow | Weak — Operating cash flow -$27M |
| Efficiency | Critical — ROE -204%, ROA -56.9% |
Ownership (TPST)
| Insider Ownership | +34.26% |
|---|---|
| Institutional Ownership | +28.49% |
| Shares Outstanding | 14.81M |
| Float | 9.27M |
| Short % of Float | +6.85% |
Source: Nexqual, June 10, 2026 at 04:40 UTC.
Leadership (TPST)
Tempest Therapeutics, Inc. is led by Matthew Angel (age 43), President, CEO & Director, per Nexqual as of June 10, 2026 at 04:40 UTC.
| President, CEO & Director | Matthew Angel (age 43) |
|---|---|
| CFO, Head of Corporate Strategy & Secretary | Nicholas Maestas (age 44) |
Major Backers & Investors (TPST)
Notable institutional backers of Tempest Therapeutics, Inc. include Versant Venture Management, LLC, Fidelity, FMR, LLC, according to Nexqual as of June 10, 2026 at 04:40 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Versant Venture Management, LLC | 1.82% |
| Fidelity | 0.61% |
| FMR, LLC | 0.22% |
| Sabby Management, LLC | 0.12% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 3.63% |
| Geode Capital | 0.59% |
| BlackRock | 0.26% |
| Dimensional Fund Advisors | 0.13% |
Source: Nexqual, June 10, 2026 at 04:40 UTC.
From Tempest Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-30)
Key Strengths & Strategy (as disclosed to the SEC)
- We expect this strategy to allow us to pursue parallel development of multiple programs while managing internal cash resources and extending our operational runway.   Our Pipeline Our product development pipeline consists of the following product candidates:   1. "RCC" renal cancer; "CCA" cholangiocarcinoma; "FPI" First Patient In; "SLE" lupus.
Partnerships
- On February 3, 2026, the Restated Factor Services Agreement was assigned to us in connection with the Closing pursuant to the Asset Purchase Agreement.
- Roche Collaboration Agreement In February 2021, we entered into a collaboration agreement with F.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RNAZ | TransCode Therapeutics, Inc. | USD 4.98 | ▼ 11.07% |
| AVTX | Avalo Therapeutics, Inc. | USD 12.9 | ▼ 1.53% |
| CDIO | Cardio Diagnostics Holdings Inc | USD 1.94 | ▼ 1.02% |
| ABVC | ABVC Biopharma, Inc. | USD 1.32 | ▼ 0.75% |
| ENSC | Ensysce Biosciences, Inc. | USD 0.25 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 04:40 UTC. This page is informational and not investment advice.